European Society for Medical Oncology

Oncology & Cancer

High response rate in phase I/II paediatric brain cancer trial

A high response rate with a single drug in a phase I/II trial of paediatric brain tumour has set the stage for combination therapy with higher response and lower toxicity, researchers reported at the ESMO 2016 Congress in ...

Oncology & Cancer

Afatinib improves progression-free survival in head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based ...

Oncology & Cancer

Patients with advanced, incurable cancer denied palliative care

Many patients with advanced, incurable cancer do not receive any palliative care, reveals new research to be presented later this month at the ESMO 2014 Congress in Madrid, Spain, 26-30 September. The findings are astonishing ...

page 6 from 34